A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02013050 |
Recruitment Status :
Completed
First Posted : December 17, 2013
Results First Posted : July 31, 2017
Last Update Posted : August 28, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Oral Mucositis | Drug: SGX942 Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 111 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck |
Study Start Date : | December 2013 |
Actual Primary Completion Date : | December 2015 |
Actual Study Completion Date : | September 2016 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo
Control
|
Drug: Placebo |
Experimental: SGX942
Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg
|
Drug: SGX942 |
- Duration of Severe Oral Mucositis (SOM) [ Time Frame: 4 weeks after end of therapy ]Duration of SOM was defined as the number of days from the onset of SOM until resolution of SOM. If the patient did not meet the requirements for resolution of SOM by the 1-month follow up visit, he/she was considered censored at the 1-month follow-up visit (or point of discontinuation of the study, if the patient had discontinued prior to the end of planned treatment). Patients who did not experience SOM were assigned a duration of 0.01. OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4.
- Residual Severe Oral Mucositis (SOM) [ Time Frame: 4 weeks after end of therapy ]OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4. SOM is defined as a WHO score of greater than or equal to 3.
- Duration of Severe Oral Mucositis (SOM) [ Time Frame: 4 weeks after end of therapy ]OM was evaluated using the published World Health Organization (WHO) OM grading scale that uses a scale of 0 to 4. SOM is defined as a WHO score of greater than or equal to 3.
- Incidence of Clinically Reported, Non-fungal Infections [ Time Frame: 4 weeks after end of therapy ]
- Percent of Patients With RECIST 1.1 Classification of "Complete Response" [ Time Frame: 4 weeks after end of therapy ]
The RECIST 1.1 scoring system evaluates both the defined (target) tumor, the non-target lesions, and the appearance of new lesions on radiologic scans as follows:
Target Lesion :
Complete Response (CR): All target lesions gone Partial Response (PR): >30% decrease from Baseline Progressive Disease (PD): >20% increase from smallest sum of longest diameter recorded since treatment started (best response) Stable Disease (SD): Neither PD nor PR
Non-Target Lesion:
Complete Response (CR): All non-target lesions gone,Tumor markers gone Stable Disease (SD): Persistence of ≥1 non-target lesion, Tumor marker level elevated Progressive Disease: Enlargement of non-target lesions
- Duration of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin [ Time Frame: 4 weeks after end of therapy ]
- Incidence of Severe Oral Mucositis (SOM) in Patients Receiving Every 3rd Week Cisplatin [ Time Frame: 4 weeks after end of therapy ]
- Survival [ Time Frame: 12 months after end of therapy ]
- Percent of Patients With RECIST 1.1 Classification of "Complete Response" [ Time Frame: 12 months after end of therapy ]
The RECIST 1.1 scoring system evaluates both the defined (target) tumor, the non-target lesions, and the appearance of new lesions on radiologic scans as follows:
Target Lesion :
Complete Response (CR): All target lesions gone Partial Response (PR): >30% decrease from Baseline Progressive Disease (PD): >20% increase from smallest sum of longest diameter recorded since treatment started (best response) Stable Disease (SD): Neither PD nor PR
Non-Target Lesion:
Complete Response (CR): All non-target lesions gone,Tumor markers gone Stable Disease (SD): Persistence of ≥1 non-target lesion, Tumor marker level elevated Progressive Disease: Enlargement of non-target lesions

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Biopsy-proven non-metastatic squamous cell carcinoma of the mouth or oropharynx and is planned to receive a standard course of concomitant CRT.
- Patients who have received surgery are eligible if surgery is performed within 6 weeks prior to study initiation.
- Planned to receive standard cisplatin chemotherapy administered either weekly or every third week.
- Must be able to read and understand informed consent
- Adequate birth control methods for the duration of the study
Exclusion Criteria:
- Current mucositis.
- Prior radiation to the head and neck.
- Chemotherapy treatment within the previous 12 months.
- Tumors of the lips, sinuses, salivary glands or nasopharynx.
- Unknown primary tumor.
- Stage 4c metastases.
- Evidence of significant hepatic, hematologic, or immunologic disease.
- Women who are pregnant or breast-feeding.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02013050
United States, Kentucky | |
Markey Cancer Center-University of Kentucky | |
Lexington, Kentucky, United States, 40536 |
Responsible Party: | Soligenix |
ClinicalTrials.gov Identifier: | NCT02013050 |
Other Study ID Numbers: |
IDR-OM-01 |
First Posted: | December 17, 2013 Key Record Dates |
Results First Posted: | July 31, 2017 |
Last Update Posted: | August 28, 2017 |
Last Verified: | July 2017 |
Mucositis Stomatitis Gastroenteritis Gastrointestinal Diseases |
Digestive System Diseases Mouth Diseases Stomatognathic Diseases |